Company intelligence / Profile preview

Aleutian Therapeutics

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Aleutian Therapeutics is developing a gene-editing approach to create universal donor stem cells that are invisible to the immune system, aiming initially at a cure for Type 1 diabetes. The company is currently at the pre-clinical stage and has not yet reported clinical results.

Therapeutic areas: EndocrinologyOther
Modalities: Gene editingStem cell therapyCell therapyBiologic (by extension from stem cell-based therapies)
Industry: Biotech

Beyond the preview

Go deeper on Aleutian Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aleutian Therapeutics.

Explore the full profile